To access this element change to forms mode OFF
Grant Award View - GA177523
Gold–based drugs for the effective treatment of ovarian cancer
GA ID:
GA177523
Agency:
Department of Industry, Science and Resources
Approval Date:
16-Jun-2021
Publish Date:
19-Jul-2021
Category:
Scientific Research
Grant Term:
15-Jul-2021 to 7-Feb-2025
Value (AUD):
$965,992.00
(GST inclusive where applicable)
One-off/Ad hoc:
No
Aggregate Grant Award:
No
PBS Program Name:
DISR 21/22 Investing in science, technology and commercialisation
Grant Program:
Global Science and Technology Diplomacy Fund
Grant Activity:
Gold–based drugs for the effective treatment of ovarian cancer
Purpose:
The project enables the clinical progression of a new class of drugs for ovarian cancer treatment with superior selectivity and activity for otherwise drug–resistant cancer cells.
This multidisciplinary project will:
• build structure–activity relationships (SARs) around targeted modifications of our patented gold compounds for superior in vivo delivery
• leverage access to bio–banks in India and Australia ensuring bio–activity across patient populations
• measure the safety of in vivo, bio–distribution and efficacy in animal models to deliver a clinical trial case to the FDA.
Engaged in this project will be multiple academic and industry partners transnationally, which is a flagship for RMIT’s research translation success whilst expanding the Institute's commitment to India.
GO ID:
GO Title:
Australia-India Strategic Research Fund (AISRF)
Internal Reference ID:
AIRXII000200
Selection Process:
Open Competitive
Confidentiality - Contract:
No
Confidentiality - Outputs:
No
Grant Recipient Details
Recipient Name:
ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY
Recipient ABN:
49 781 030 034
Grant Recipient Location
Suburb:
MELBOURNE
Town/City:
MELBOURNE
Postcode:
3000
State/Territory:
VIC
Country:
AUSTRALIA
Grant Delivery Location
State/Territory:
VIC
Postcode:
3000
Country:
AUSTRALIA